Therapeutic kinase inhibitors
著者
書誌事項
Therapeutic kinase inhibitors
(Current topics in microbiology and immunology, v. 355)
Springer, c2012
大学図書館所蔵 全7件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
内容説明・目次
内容説明
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as "chemotherapy" and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
目次
Preface.- Fundamentals.- Setting up a Kinase Discovery and Development Project.-Drug Efficacy Testing in Mice.- Kinase Targets and Disease.- Gastrointestinal Stromal Tumors (GISTS).-EGFR-Mutant Lung Cancer.- Targeting Oncogenic BRAF in Human Cancer.- Beyond BRAF in Melanoma.- JAK-mutant Myeloproliferative Neoplasms.- Will Kinase Inhibitors Make It as Glioblastoma Drugs?.- Perspectives.- Predictive Genomic Biomarkers.- Epigenetic Biomarkers.- Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer.- Subject Index
「Nielsen BookData」 より